Form 4/A for PCSA Processa Pharmaceuticals, Inc.
Accepted 2023-01-04 00:00:00 ET · period of report 2022-08-05 · accession 0001567619-23-000303 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2023-01-04 | 2022-08-05 | PCSA | Yorke Justin W | Dir | M - OptEx | — | +1,169 | 14.9K | +9% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-05 | M | A | 1,169 | — | 14,885 | D | — | — | (F1) Vesting of time-based restricted shares. (F2) Previous filing inadvertently underreported shares beneficially owned by the reporting person. |